Related Experiment Videos
Chlorambucil-associated pneumonitis
B Crestani1, A Jaccard, D Israël-Biet
1Immuno-Hematology Unit, Hôpital Saint Louis, Paris, France.
Insights
A patient experienced interstitial pneumonitis during chlorambucil treatment for chronic lymphocytic leukemia. Lung inflammation resolved after stopping the drug, suggesting a drug-induced hypersensitivity pneumonitis.
Area of Science:
- Pulmonology
- Oncology
- Immunology
Background:
- Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy.
- Chlorambucil is an alkylating agent used in CLL treatment.
- Interstitial pneumonitis is a potential adverse effect of chemotherapy.
Observation:
- A patient on chlorambucil for CLL developed interstitial pneumonitis.
- Bronchoalveolar lavage revealed T-lymphocytic alveolitis.
- Blood lymphocytes were predominantly B-cell phenotype, contrasting with lung findings.
Findings:
- Discontinuation of chlorambucil led to rapid clinical improvement.
- Persistent T-lymphocytic alveolitis with a CD8+ phenotype was observed post-treatment.
- The lung immune profile resembled drug-induced hypersensitivity pneumonitis.
Implications:
- This case highlights chlorambucil-induced hypersensitivity pneumonitis.
- T-lymphocytic alveolitis may be a marker for drug-induced lung injury.
- Careful monitoring for pulmonary complications is crucial in patients receiving chlorambucil.
Abstract:
A patient developed an interstitial pneumonitis while receiving chlorambucil for a chronic lymphocytic leukemia (cumulative dose, 8,340 mg). Withdrawal of drug treatment was followed by rapid improvement in the clinical condition. Bronchoalveolar lavage showed a T-lymphocytic alveolitis, whereas blood lymphocytes were predominantly of the B phenotype. The T-lymphocytic alveolitis persisted 6 weeks after drug therapy cessation with a predominant CD8+ phenotype, as observed in some hypersensitivity pneumonitis induced by drugs.